Aaron N Hata

Aaron N Hata

UNVERIFIED PROFILE

Are you Aaron N Hata?   Register this Author

Register author
Aaron N Hata

Aaron N Hata

Publications by authors named "Aaron N Hata"

Are you Aaron N Hata?   Register this Author

50Publications

1545Reads

33Profile Views

Resistance looms for KRAS inhibitors.

Nat Med 2020 Feb;26(2):169-170

Novartis Institutes of Biomedical Research, Cambridge, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-020-0765-zDOI Listing
February 2020

Investigating New Mechanisms of Acquired Resistance to Targeted Therapies: If You Hit Them Harder, Do They Get Up Differently?

Cancer Res 2020 Jan;80(1):25-26

Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, Virginia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-19-3405DOI Listing
January 2020

Can the Help Match the Hype? KRAS-Specific Inhibitors and Beyond.

Cancer Discov 2020 Jan;10(1):20-22

Divsion of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-1255DOI Listing
January 2020

Treatment with Next-Generation ALK Inhibitors Fuels Plasma Mutation Diversity.

Clin Cancer Res 2019 Nov 29;25(22):6662-6670. Epub 2019 Jul 29.

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-1436DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858956PMC
November 2019

Sequence, Treat, Repeat: Addressing Resistance in EGFR-Mutant NSCLC.

J Thorac Oncol 2019 Nov;14(11):1875-1877

Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.07.014DOI Listing
November 2019

Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion.

J Thorac Oncol 2019 Oct;14(10):e226-e228

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.05.046DOI Listing
October 2019

Distinct evolutionary paths to TKI resistance in NSCLC.

Cell Cycle 2018 29;17(3):298-299. Epub 2018 Jan 29.

a Massachusetts General Hospital Cancer Center , Charlestown , MA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/15384101.2016.1
Publisher Site
http://dx.doi.org/10.1080/15384101.2016.1221024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914907PMC
September 2019

Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylation.

Nature 2019 09 28;573(7772):139-143. Epub 2019 Aug 28.

Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41586-019-1511-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728214PMC
September 2019

Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities.

Pharmacol Ther 2019 01 16;193:20-30. Epub 2018 Aug 16.

Massachusetts General Hospital Cancer Center, Charlestown, MA, USA; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2018.08.007DOI Listing
January 2019

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

J Clin Oncol 2018 04 26;36(12):1199-1206. Epub 2018 Jan 26.

Jessica J. Lin, Satoshi Yoda, Beow Y. Yeap, Ibiayi Dagogo-Jack, Nicholas A. Jessop, Ginger Y. Jiang, Long P. Le, Aaron N. Hata, Justin F. Gainor, Anthony J. Iafrate, and Alice T. Shaw, Massachusetts General Hospital, Boston; Alexa B. Schrock, Kyle Gowen, Philip J. Stephens, Jeffrey S. Ross, Siraj M. Ali, and Vincent A. Miller, Foundation Medicine, Cambridge, MA; Viola W. Zhu and Sai-Hong Ignatius Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; Melissa L. Johnson, Sarah Cannon Research Institute; and Christine M. Lovly, Vanderbilt-Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.2294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903999PMC
April 2018

Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.

J Thorac Oncol 2017 03 2;12(3):458-466. Epub 2016 Nov 2.

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts; Department of Pathology, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.10.015DOI Listing
March 2017

Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment.

J Thorac Oncol 2016 11 24;11(11):1869-1878. Epub 2016 Aug 24.

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts; Department of Pathology, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.08.134DOI Listing
November 2016

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.

Cancer Discov 2015 May 20;5(5):475-87. Epub 2015 Apr 20.

Virginia Commonwealth University Philips Institute for Oral Health Research, School of Dentistry and Massey Cancer Center, Richmond, Virginia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-15-0011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727530PMC
May 2015

Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.

Cancer Res 2014 Jun 27;74(11):3146-56. Epub 2014 Mar 27.

Authors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, MassachusettsAuthors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-3728DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046322PMC
June 2014

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.

Cancer Discov 2014 Jan 25;4(1):42-52. Epub 2013 Oct 25.

1Massachusetts General Hospital Cancer Center; 2Department of Medicine, Harvard Medical School; 3Division of Gastroenterology, Department of Medicine, Tufts Medical Center; 4Department of Pathology, Massachusetts General Hospital, Boston; and 5Radiation Oncology, Steele Lab for Tumor Biology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0315DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973435PMC
January 2014

Extracellular loop II modulates GTP sensitivity of the prostaglandin EP3 receptor.

Mol Pharmacol 2013 Jan 18;83(1):206-16. Epub 2012 Oct 18.

Division of Nephrology, Vanderbilt University School of Medicine, S3223 MCN, 1161 21st Avenue, Nashville, TN 37232-2372, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.112.080473DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533480PMC
January 2013

IR and Raman spectra of beta''-(BEDT-TTF)(2)RCH(2)SO(3) (R = SF(5), CF(3)): dimerization related to hydrogen bonding.

Phys Chem Chem Phys 2009 May 12;11(20):3910-20. Epub 2009 Mar 12.

Institute of Molecular Physics, Polish Academy of Sciences, Smoluchowskiego, Poznań, Poland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/b822253cDOI Listing
May 2009

Incorporation of selenomethionine into induced intracytoplasmic membrane proteins of Rhodobacter species.

J Struct Funct Genomics 2005 ;6(2-3):95-102

Biosciences Division, Argonne National Laboratory, 9700 S. Cass Avenue, Argonne, IL 60439, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10969-005-1936-3DOI Listing
June 2006

Characterization of a rabbit kidney prostaglandin F(2{alpha}) receptor exhibiting G(i)-restricted signaling that inhibits water absorption in the collecting duct.

J Biol Chem 2005 Oct 10;280(41):35028-37. Epub 2005 Aug 10.

Departments of Cellular and Molecular Medicine, Kidney Research Centre, Faculty of Medicine, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M505852200DOI Listing
October 2005

Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2.

J Biol Chem 2005 Sep 19;280(37):32442-51. Epub 2005 Jul 19.

Department of Pharmacology, the Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.

View Article

Download full-text PDF

Source
http://www.jbc.org/content/early/2005/07/19/jbc.M502563200.f
Web Search
http://www.jbc.org/cgi/doi/10.1074/jbc.M502563200
Publisher Site
http://dx.doi.org/10.1074/jbc.M502563200DOI Listing
September 2005

Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2.

Mol Pharmacol 2005 Mar 24;67(3):640-7. Epub 2004 Nov 24.

Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232-2372, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.104.007971DOI Listing
March 2005

Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation.

Pharmacol Ther 2004 Aug;103(2):147-66

Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S016372580400096
Publisher Site
http://dx.doi.org/10.1016/j.pharmthera.2004.06.003DOI Listing
August 2004

Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation.

J Biol Chem 2004 Jul 3;279(28):29797-804. Epub 2004 May 3.

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M313989200DOI Listing
July 2004

Expression and molecular pharmacology of the mouse CRTH2 receptor.

J Pharmacol Exp Ther 2003 Aug 29;306(2):463-70. Epub 2003 Apr 29.

Department of Pharmacology,Vanderbilt University, Nashville, Tennessee 37232-2372, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.103.050955DOI Listing
August 2003